Charite Research Organisation GmbH
Verified site
Berlin, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial focuses on adults with moderate to severe Psoriasis. It evaluates two investigational injectable medicines, ABBV-295 and ABBV-066, the latter containing the active protein RISANKIZUMAB, compared with a placebo. The purpose of the study is to determine how well these agents improve skin lesions and how safe they are.
Participants receive a series of injections over several weeks while attending regular clinic visits. At each visit, doctors check the skin, record any side effects, and measure body weight. The study continues for a few months, after which the data are collected for analysis.
Improvement is measured using the Psoriasis Area and Severity Index, a scoring system that rates the redness, thickness and area of skin plaques; a high score means more severe disease, and a reduction indicates improvement. Safety is monitored by recording any adverse events, which are any unwanted medical occurrences during the trial.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
3 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Berlin, Germany
Frankfurt, Germany
Rostock, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental medicine that is given by injection. In this study it is being tested to see if it can improve the skin symptoms of adults with moderate to severe psoriasis. The drug is supplied as a liquid that can be injected directly into the body. Researchers are looking at how well it works on its own or together with other treatments, and they are also checking its safety.
is the study code for a medicine called risankizumab, which is also given by injection. It is provided in a pre‑filled syringe for easy use. In the trial, this medicine is being evaluated for its ability to reduce the redness, thickness, and scaling of psoriasis‑affected skin. The study will measure how effective it is and monitor any side effects.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.